Marianna C.
- Country
- Italy
- Department
- 2600: S.C. Ematologia Day Hospital (Blocco Sud)
Research Overview
- Long-term Safety of Asciminib in Patients With Philadelphia Chromosome-Positive CML or ALL Continuing From Parent Studies
- Efficacy and Safety Evaluation of Selinexor and Ruxolitinib in Treatment-Naïve Myelofibrosis Patients: A Phase 1/3 Clinical Trial
- Evaluation of TL-895 in Myelofibrosis, Indolent Systemic Mastocytosis, and Mast Cell Activation Syndrome: A Phase 2 Multicenter Study
Data & Insights
Has run more than one trial at 127 of 243 partner sites.
Specializations
Myelofibrosis Research
The investigator specializes in treating myelofibrosis, including various disease states such as JAK inhibitor-naïve and treatment-refractory cases. Their research encompasses both monotherapy and combination treatment approaches for patients with different risk levels.
- Primary Myelofibrosis
- Post-Essential Thrombocythemia Myelofibrosis
- Post-Polycythemia Vera Myelofibrosis
Chronic Myeloid Leukemia
The investigator focuses on treating Chronic Myeloid Leukemia, particularly in the chronic phase. Their expertise includes managing both newly diagnosed cases and patients who have received prior treatments but haven't achieved optimal responses.
- Philadelphia Chromosome Positive CML
- Treatment-Resistant CML
- Molecular Response Assessment
Rare Blood Disorders
The investigator has expertise in treating rare hematologic conditions, including Indolent Systemic Mastocytosis and Mast Cell Activation Syndrome. Their work encompasses both monoclonal and non-monoclonal variants of these conditions.
- Advanced Hematologic Malignancies
- Systemic Mastocytosis
- Mast Cell Disorders
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.